- Home
- FULC vs AURA Comparison
FULC vs AURA Comparison
Compare FULC & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FULC | AURA |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 468.1M | 396.8M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FULC | AURA |
|---|---|---|
| Price | $9.87 | $5.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $16.38 | ★ $20.20 |
| AVG Volume (30 Days) | ★ 1.2M | 203.0K |
| Earning Date | 02-24-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2752.05 | N/A |
| 52 Week Low | $2.32 | $4.35 |
| 52 Week High | $15.74 | $8.27 |
Technical Indicators
Market Signals| Indicator | FULC | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 40.87 | 33.87 |
| Support Level | $9.77 | $5.02 |
| Resistance Level | $10.47 | $5.46 |
| Average True Range (ATR) | 0.70 | 0.35 |
| MACD | -0.32 | -0.07 |
| Stochastic Oscillator | 8.63 | 6.34 |
Price Performance
Historical ComparisonAbout FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.